Represented Oklahoma Medical Research Foundation (OMRF) in a suit against Eli Lilly in the Western District of Oklahoma. OMRF alleged patent infringement and breach of a license agreement in connection with Eli Lilly's sales of Xigris, the first FDA-approved drug to treat severe sepsis. The suit settled on the eve of trial after more than 60 depositions, production of more than one million pages of documents by Eli Lilly, and a Markman hearing resulting in a claim construction favorable to our client.

Oklahoma Med. Research Found. v. Eli Lilly & Co., No. 01-0456 (W.D. Okla. filed Mar. 15, 2001).

Experience Center

Match our Experience to Your Needs

Experience Highlights

Internal investigation regarding potential Foreign Corrupt Practices Act violations
Internal investigation on behalf of a board of directors of a Fortune 500 company regarding potential Foreign Corrupt Practices Act more
Represented Landmark Communications Inc. in sale of The Weather Channel
Represented Landmark Communications Inc. in the sale of its weather-related businesses, including The Weather Channel and weather.com, to a more
Executive compensation and employee benefits matters for a Philadelphia holding company
Represented a Philadelphia financial institution on executive compensation and employee benefits matters. Assisted in the design and drafting of a more
Multifaceted debt refinancing transaction for Interface Inc.
Represented Interface Inc., a worldwide leader in the design, production and sales of modular carpet, in its approximately $300 million public debt more